Diabetes and Surgery: Preoperative and Postoperative Glycemic Management Guidelines

Surgery represents a significant physiological stressor that triggers a cascade of neuroendocrine responses. The release of stress hormones (cortisol, catecholamines, glucagon, and growth hormone) during surgery induces insulin resistance and stimulates hepatic glucose production, causing acute hyperglycemia. In patients with diabetes, perioperative hyperglycemia is associated with poor clinical outcomes, including impaired wound healing, increased surgical site infection rates, and prolonged hospital stays. Managing blood glucose effectively before, during, and after surgery is a critical collaborative effort between the patient, surgeon, anesthesiologist, and endocrinologist.

The Impact of Hyperglycemia on Surgical Outcomes

Elevated blood sugar levels impair immune function, specifically compromising neutrophil chemotaxis, phagocytosis, and intracellular bactericidal activity. This increases the risk of postoperative infections. Additionally, hyperglycemia alters collagen synthesis and capillary endothelial function, delaying wound tensile strength recovery. Clinical guidelines from the American Diabetes Association (ADA) recommend maintaining a perioperative blood glucose target between 100 and 180 mg/dL (5.6 to 10.0 mmol/L) for most patients to balance the benefits of avoiding hyperglycemia while minimizing the risk of severe hypoglycemia. High-risk patients should optimize their HbA1c (ideally below 8.0 percent, or below 7.0 percent if feasible without hypoglycemia) prior to elective surgeries.

💡 💡 Hold SGLT2 Inhibitors to Avoid eDKA

SGLT2 inhibitors (such as empagliflozin or dapagliflozin) must be discontinued at least 3 to 4 days prior to any scheduled major surgical procedure. This clinical precaution is necessary to prevent euglycemic diabetic ketoacidosis (eDKA), a metabolic emergency characterized by ketoacidosis despite normal blood glucose levels, triggered by the stress of surgery.

Preoperative Medication Adjustments

To prevent hypoglycemia during preoperative fasting and minimize the risk of drug-related complications, medication regimens must be adjusted before surgery. Guidelines typically suggest the following:

• Metformin: Discontinue 24 hours prior to surgery or on the morning of the procedure. It can be resumed postoperatively once the patient is tolerating oral intake and renal function is verified as stable. This prevents lactic acidosis in case of perioperative acute kidney injury.
• Sulfonylureas: (e.g., glipizide, glimepiride) Hold on the morning of surgery due to the high risk of hypoglycemia while fasting. For more details on these medications, refer to Oral Diabetes Medications.
• SGLT2 Inhibitors: Discontinue 3 to 4 days prior to major surgery. This is critical to prevent eDKA under surgical stress.
• GLP-1 Receptor Agonists: Often held for a week prior to surgery due to delayed gastric emptying, which increases the risk of aspiration during anesthesia induction.
• Basal Insulin: Patients taking long-acting insulin must continue their basal coverage to prevent ketosis. However, the dose should be reduced by 20 percent to 30 percent the night before or the morning of surgery. For details on basal insulin, see Starting Insulin Therapy.
• Rapid-Acting Insulin: Hold on the morning of surgery while fasting, unless needed as a correction dose for severe hyperglycemia.

These adjustments are highly individualized and should be confirmed in writing by the surgical team.

Intraoperative and Postoperative Glycemic Management

During surgery, blood glucose is monitored frequently (every 1 to 2 hours for major procedures). For minor outpatient surgeries, patients may monitor their own glucose using fingersticks. For major or prolonged procedures, an intravenous insulin infusion may be initiated to maintain tight glycemic control. Postoperatively, blood glucose monitoring continues. Oral diabetes medications should only be resumed once the patient is tolerating a normal diet and renal function is documented as stable, particularly for metformin. During the recovery phase, patients must monitor for signs of wound infection (redness, warmth, drainage) and contact their surgeon immediately if blood sugar levels remain persistently elevated, which can delay recovery.

💡 Frequently Asked Questions (FAQ)

Q1: Why must SGLT2 inhibitors be stopped so far in advance of surgery?
A1: SGLT2 inhibitors promote glucose excretion in urine, which can hide ketoacidosis by keeping blood sugar levels normal or near-normal (under 250 mg/dL). Discontinuing them 3 to 4 days prior ensures the drug is fully cleared from the system, preventing the risk of euglycemic DKA under surgical stress.

Q2: What should I do if my blood sugar is high on the morning of my surgery?
A2: Contact your surgical team or anesthesiologist immediately. Do not administer rapid-acting insulin unless specifically instructed to do so by a physician, as this could cause hypoglycemia during the procedure. The surgical team will evaluate and manage your glucose levels at the hospital.

Q3: How does poor glycemic control affect my risk of infection after surgery?
A3: High blood sugar levels impair the function of white blood cells, making it harder for your body to fight off bacteria at the surgical site. It also slows down blood circulation and tissue oxygenation, which delays wound healing and increases the risk of complications.

📚 References & Sources

1. American Diabetes Association (2024). Diabetes Care in the Hospital: Standards of Care in Diabetes—2024. Diabetes Care, 47(Suppl. 1), S295-S312.
2. Joint British Diabetes Societies for Inpatient Care (JBDS-IP) (2021). Guidelines for the Management of Diabetes in Adults Undergoing Surgery.